The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | VIOLA: azacitidine and lenalidomide salvage therapy for AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, provides an outline of the key findings from his study on combination therapy of lenalidomide and azacitidine in salvage therapy of relapsed acute myeloid leukemia (AML) patients post-allogeneic stem cell transplantation. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
